Patients with prophylactic administration of posaconazole for invasive fungal infections in severely immunocompromised states such as hematopoietic stem cell transplantation or hematologic malignancies where neutropenia is predicted Patients treated with posaconazole for aspergillosis, fusariosis, mucormycosis, coccidioidosis, chromoblastomycosis, and mycetoma Patients treated with posaconazole for oropharyngeal candidiasis The trial will be a randomised controlled trial with the above subjec
Conditions
Interventions
None listed
Sponsors
Saiseikai Futsukaichi Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with prophylactic administration of posaconazole for invasive fungal infections in severely immunocompromised states such as hematopoietic stem cell transplantation or hematologic malignancies where neutropenia is predicted Patients treated with posaconazole for aspergillosis, fusariosis, mucormycosis, coccidioidosis, chromoblastomycosis, and mycetoma Patients treated with posaconazole for oropharyngeal candidiasis
Exclusion criteria
Exclusion criteria: Letters/correspondence, case reports, relevant reviews, no controlled arm, unclear outcomes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hypokalemia | — |
Secondary
| Measure | Time frame |
|---|---|
| <Secondary outcomes> rhabdomyolysis, pseudohyperaldosteronism, hypertension <Subgroup Analysis> (1) Prophylactic administration of posaconazole for invasive fungal infections in severe immunodeficiency states such as hematopoietic stem cell transplantation or hematologic malignancies where neutropenia is expected (2) Fungal infections (invasive aspergillosis, fusariasis, mucormycosis, coccidioidosis, chromoblastomycosis, and mycetoma) (3) Investigate with antifungal agents or placebo, respectively Subgroup analysis will be performed in each of the above. <Sensitivity analysis> Meta-analysis will be performed by excluding trials with a risk of bias for "High" in ROB2. | — |
Countries
Japan
Contacts
Public ContactYuki Nakano
Saiseikai Futsukaichi Hospital Department of pharmacy
Outcome results
None listed